サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1744423

遺伝性痙性対麻痺（HSP）の世界市場：薬剤別、重症度別、流通チャネル別、地域別、機会、予測、2018年～2032年

Hereditary Spastic Paraplegia (HSP) Market Assessment, By Medication, By Severity, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 242 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
遺伝性痙性対麻痺（HSP）の世界市場：薬剤別、重症度別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月10日
発行: Market Xcel - Markets and Data
ページ情報: 英文 242 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝性痙性対麻痺（HSP）の市場規模は、予測期間の2025年～2032年のCAGRが14.65％となり、2024年の1億1,590万米ドルから2032年には3億4,600万米ドルに成長すると予測されています。市場の開拓を支えているのは、HSP症例の増加、遺伝子研究の進歩、支援的な規制措置、研究開発活動に対する投資の増加です。さらに、遺伝子編集プラットフォームや神経リハビリテーションソリューションの進歩も、市場の成長を促進する上で重要な役割を果たすと予想されます。

高度な診断ソリューションと遺伝子治療への重点の高まりも、市場の成長と拡大を支えています。全ゲノムシーケンシングと次世代シーケンシングは、早期の治療介入を可能にし、診断精度を向上させています。研究者はまた、HSPの根本的な原因に対処するため、遺伝子サイレンシングや置換戦略を模索しています。製薬会社や学術研究機関は、新規治療法の安全性と有効性を試験し、遺伝子型と表現型の相関を理解するため、前臨床研究活動に投資しています。

さらに、世界中のヘルスケアシステムは、希少疾患や神経疾患の診断効率や治療法の改善に注力しており、市場の拡大を支えています。様々な政府が、HSPを含む希少疾患の脅威の増大と闘うための政策を実施し、製薬会社にインセンティブを与えるために税額控除、早期承認、研究助成金を提供しています。

当レポートでは、世界の遺伝性痙性対麻痺（HSP）市場について調査し、市場の概要とともに、薬剤別、重症度別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 薬剤別
      • 骨格筋弛緩薬
      • 抗不安薬
      • ベンゾジアゼピン
      • 非ステロイド性抗炎症薬（NSAID）
      • その他
    • 重症度別
      • 軽度
      • 中等度
      • 重度
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第5章 北米の遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第6章 欧州の遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第7章 アジア太平洋の遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの遺伝性痙性対麻痺（HSP）市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第10章 需要供給分析

  • サプライチェーン分析
  • バリューチェーン分析

第11章 ポーターのファイブフォース分析

第12章 PESTLE分析

第13章 価格分析

第14章 市場力学

  • 市場の促進要因
  • 市場の課題

第15章 市場動向と発展

  • 臨床試験
  • 新たな開発と革新

第16章 ケーススタディ

第17章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Novartis A.G.
    • Pfizer Inc.
    • BlackfinBio Limited
    • Sanofi S.A.
    • Elpida Therapeutics
    • Genetic Cures for Kids Inc.
    • Daiichi Sankyo Company, Limited

第18章 戦略的提言

第19章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 3. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 4. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Hereditary Spastic Paraplegia (HSP) Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 7. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 8. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 9. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 12. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 13. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 14. United States Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 16. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 17. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 18. Canada Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 20. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 21. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 22. Mexico Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 24. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 25. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 26. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 30. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 31. Germany Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 33. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 34. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 35. France Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 37. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 38. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 39. Italy Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 41. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 42. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 43. United Kingdom Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 45. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 46. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 47. Russia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 49. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 50. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 51. Netherlands Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 53. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 54. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 55. Spain Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 57. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 58. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 59. Turkey Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 61. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 62. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 63. Poland Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 65. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 66. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 67. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 71. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 72. Brazil Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 74. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 75. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 76. Argentina Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 78. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 79. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 80. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 82. India Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 83. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 84. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 85. India Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 87. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 88. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 89. China Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 91. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 92. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 93. Japan Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 95. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 96. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 97. Australia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 99. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 100. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 101. Vietnam Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 103. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 104. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 105. South Korea Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 107. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 108. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 109. Indonesia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 111. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 112. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 113. Philippines Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 115. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 116. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 117. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 120. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 121. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 122. Saudi Arabia Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 124. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 125. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 126. UAE Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Hereditary Spastic Paraplegia (HSP) Market, By Value, In USD Million, 2018-2032F
  • Figure 128. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Medication, 2018-2032F
  • Figure 129. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Severity, 2018-2032F
  • Figure 130. South Africa Hereditary Spastic Paraplegia (HSP) Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Medication Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 132. By Severity Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024
目次
Product Code: MX13280

Global hereditary spastic paraplegia (HSP) market is projected to witness a CAGR of 14.65% during the forecast period 2025-2032, growing from USD 115.90 million in 2024 to USD 346 million in 2032. The market's growth is supported by the rising cases of HSP, advancements in genetic research, supportive regulatory measures, and rising investments towards research and development activities. Additionally, advancements in gene editing platforms and neurorehabilitation solutions are also expected to play a significant role in driving the growth of the market.

Increasing emphasis on advanced diagnostic solutions and gene therapies is also supporting the market's growth and expansion. Whole-exome sequencing and next-generation sequencing are allowing early therapeutic interventions and improving diagnostic accuracy. Researchers are also exploring gene silencing and replacement strategies to address the underlying cause of HSP. Pharmaceutical companies and academic and research institutions are investing in preclinical research activities to test the safety and efficacy of novel therapies and understand genotype-phenotype correlations.

Moreover, healthcare systems across the globe are focusing on improving diagnostic efficiency and treatments for rare diseases and neurological disorders, supporting the market's expansion. Various governments are implementing policies to combat the growing threat of rare diseases, including HSP and providing tax credits, accelerated approvals, and research grants to incentivize pharmaceutical companies.

Increasing Regulatory Support Boosts Market Growth

Increasing support from different regulatory bodies such as the Food and Drug Administration (FDA) is accelerating the clinical evaluation and development of innovative therapeutic solutions for treating and managing neurogenetic disorders. For instance, in May 2025, BlackfinBio Limited received approval from the US FDA to begin phase 1/2 clinical trial for adeno-associated virus (AAV) gene therapy targeting HSP, Type 47. The trial aims to assess the tolerability, safety, and efficacy of the AAV gene therapy in patients with HSP, Type 47. Such approvals validate scientific advancements and incentivize pharmaceutical companies to invest in research and development activities.

Additionally, the provision of rare pediatric disease status and orphan drug designation further encourage pharmaceutical companies to pursue novel therapeutic solutions by providing benefits such as financial incentives and market exclusivity. Such supportive initiatives foster collaboration between industry leaders, clinical centers, and academic institutions, resulting in the expedition of molecular and genetic discoveries, improving treatment outcomes and bolstering the availability of treatment options, positively influencing the market's expansion.

Rising Research Activities Support Market Expansion

Advances in molecular genetics and next-generation sequencing have already identified over 80 genetic causes of HSP, laying the groundwork for variant-specific therapies. Researchers across the globe are focusing on developing gene therapies for HSP. For instance, in January 2024, a team of researchers from the Korea Research Institute of Bioscience & Biotechnology (KRIBB) developed gene therapy for HSP. The team identified the role of ARL6IP1 gene in the onset of HSP. Their findings showed that ARL6IP1 is involved in maintaining homeostasis of cellular organelles and is located in the mitochondrial associated ER membrane. The presence of a robust research environment that fosters innovations and supports development of new therapies is allowing researchers to bridge the gaps in HSP care and develop disease modifying treatments.

Hospitals Pharmacies Account for Significant Share of the Market

The segment's dominance can be attributed to the central role played by hospitals and clinics in the management and treatment of HSP. The condition requires multidisciplinary care involving physiotherapies and neurologists, among other specialists, which is only available and effectively coordinated in hospitals and clinics. Additionally, hospitals and clinics also offer medication management and comprehensive patient monitoring, which is essential for diseases such as HSP. They are equipped with the necessary technology and professionals to handle complex cases, provide patient education to improve treatment adherence, and adjust treatment regimens. Additionally, hospitals algo participate in various clinical trials to elevate the understanding of different mechanisms associated with HSP, further strengthening the segment's position. For instance, Boston Children's Hospital is conducting an observational study to better understand the role of genetic factors in HSP. The study is estimated to conclude in April 2027.

North America Holds Major Market Share

The rapid growth of the market in North America can be attributed to the availability of high fundings for rare disease research, strong presence of leading market players, availability of advanced genetic testing services, and rising incidences of HSP. As per the estimates of the Spastic Paraplegia Foundation, in the United States the HSP incidence rate is approximately 20,000.

The strong presence of leading academic and research institutions and pharmaceutical companies is supporting innovations and new product launches, driving the market's growth and expansion. In countries such as the United States, supportive framework and initiatives including the Orphan Drug Act are enabling early-stage clinical research and providing financial incentives for HSP drug development. Additionally, the rising popularity of telehealth services is improving patient access to specialists and neurologists, especially in rural locations, allowing patients to receive timely diagnosis, supporting the market's expansion.

Future Market Scenario (2025 - 2032F)

The market is expected to witness significant growth over the forecast period, due to rising awareness, technological advancements, and increasing research in curative gene therapies. With rising investments from both private and public sectors, the focus on disease-modifying treatments is increasing, bolstering the availability of therapeutic solutions that tackle the root cause of the condition and just symptomatic management. Additionally, rising emphasis on research activities to bolster the availability of new treatments for HSP is also expected to propel the market's expansion. For instance, Shanghai Sixth People's Hospital, affiliated to Shanghai Jiao Tong University School of Medicine is conducting an interventional study to explore the safety and efficacy of calcium folinate for treating patients with spastic paraplegia 56. The study is estimated to conclude in May 2030. Additionally, advancements in AI-powered diagnostic and biomarker analysis are expected to support early disease detection, providing lucrative growth opportunities for the market.

Key Players Landscape and Outlook

The leading market players are focusing on conducting clinical trials, developing new therapies, and working on improving the understanding of the genetic factors responsible for HSP. The key players are also focusing on seeking investments to support their research and development activities and bolster the availability of novel therapeutic solutions. For instance, in December 2023, BlackfinBio Limited raised approximately USD 3.7 million in seed investment to advance treatments for HSP. Such investments are expected to accelerate the translation of laboratory discoveries to therapies, improving prospects for the patient population across the globe and allowing companies to expand their presence in the industry.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Medication
      • 4.2.1.1. Skeletal Muscle Relaxants
      • 4.2.1.2. Anxiolytics
      • 4.2.1.3. Benzodiazepines
      • 4.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      • 4.2.1.5. Others
    • 4.2.2. By Severity
      • 4.2.2.1. Mild
      • 4.2.2.2. Moderate
      • 4.2.2.3. Severe
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Medication
    • 4.3.2. By Severity
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Medication
      • 5.2.1.1. Skeletal Muscle Relaxants
      • 5.2.1.2. Anxiolytics
      • 5.2.1.3. Benzodiazepines
      • 5.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      • 5.2.1.5. Others
    • 5.2.2. By Severity
      • 5.2.2.1. Mild
      • 5.2.2.2. Moderate
      • 5.2.2.3. Severe
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Medication
          • 5.3.1.2.1.1. Skeletal Muscle Relaxants
          • 5.3.1.2.1.2. Anxiolytics
          • 5.3.1.2.1.3. Benzodiazepines
          • 5.3.1.2.1.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
          • 5.3.1.2.1.5. Others
        • 5.3.1.2.2. By Severity
          • 5.3.1.2.2.1. Mild
          • 5.3.1.2.2.2. Moderate
          • 5.3.1.2.2.3. Severe
        • 5.3.1.2.3. By Distribution Channel
          • 5.3.1.2.3.1. Hospital Pharmacies
          • 5.3.1.2.3.2. Retail Pharmacies
          • 5.3.1.2.3.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Turkey
  • 6.9. Poland

7. Asia-Pacific Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Hereditary Spastic Paraplegia (HSP) Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa

10. Demand Supply Analysis

  • 10.1. Supply Chain Analysis
  • 10.2. Value Chain Analysis

11. Porter's Five Forces Analysis

12. PESTLE Analysis

13. Pricing Analysis

14. Market Dynamics

  • 14.1. Market Drivers
  • 14.2. Market Challenges

15. Market Trends and Developments

  • 15.1. Clinical Trials
  • 15.2. New Developments and Innovations

16. Case Studies

17. Competitive Landscape

  • 17.1. Competition Matrix of Top 5 Market Leaders
  • 17.2. SWOT Analysis for Top 5 Players
  • 17.3. Key Players Landscape for Top 10 Market Players
    • 17.3.1. Novartis A.G.
      • 17.3.1.1. Company Details
      • 17.3.1.2. Key Management Personnel
      • 17.3.1.3. Products and Services
      • 17.3.1.4. Financials (As Reported)
      • 17.3.1.5. Key Market Focus and Geographical Presence
      • 17.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 17.3.2. Pfizer Inc.
    • 17.3.3. BlackfinBio Limited
    • 17.3.4. Sanofi S.A.
    • 17.3.5. Elpida Therapeutics
    • 17.3.6. Genetic Cures for Kids Inc.
    • 17.3.7. Daiichi Sankyo Company, Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

18. Strategic Recommendations

19. About Us and Disclaimer